Marja T. Nevalainen, MD, PhD

Professor, Eminent Scholar, Department of Pathology and Pharmacology & Toxicology; Assistant Dean of Research, Medical College of Wisconsin; Associate Director (Education), Medical College of Wisconsin Cancer Center; Director, Prostate Cancer Center of Excellence at Medical College of Wisconsin Cancer Center

Contact Information

Education

University of Turku, School of Medicine, Turku, Finland, MD
University of Turku, Turku, Finland, Cell Biology, PhD

Biography

Marja Nevalainen, MD, PhD is an internationally recognized leader in the field of cytokine and steroid hormone signaling in prostate cancer. The focus of her laboratory is on translational prostate cancer research to develop and improve diagnostics and therapy for prostate cancer. Dr. Nevalainen holds the title of Eminent Scholar at MCW. She is also Director of Prostate Cancer Center of Excellence at MCW Cancer Center, which is a multi-disciplinary hub for prostate cancer research within the institution with an international collaborative network. Dr. Nevalainen serves as Assistant Dean for Research at MCW, and Associate Director of Education for the MCW Cancer Center. Her primary appointment is in the Department of Pathology, and a secondary appointment in the Department of Pharmacology and Toxicology. Dr. Nevalainen has extensive experience in collaborative research, mentoring and leadership from her previous roles at Sidney Kimmel Cancer Center at Thomas Jefferson University as Associate Director of Education and Vice Chair of Education in the Department of Cancer Biology.

Honors and Awards

General Medicine Board Certification

Research Experience

Janus Kinase 2
Prostate
STAT5 Transcription Factor

Research Interests

Jak-Stat signaling
Prostate cancer progression
Therapy development
Companion diagnostics
Predictive Factors
DNA repair
Radiation therapy
In vitro and in vivo models
3D tumor explant culture
Epithelial-mesenchymal transition
Cancer stem-like cell properties
Metastases models
Small molecule therapeutics

Positive STAT5 Protein and Locus Amplification Status Predicts Recurrence after Radical Prostatectomy to Assist Clinical Precision Management of Prostate Cancer.

(Haddad BR, Erickson A, Udhane V, LaViolette PS, Rone JD, Kallajoki MA, See WA, Rannikko A, Mirtti T, Nevalainen MT.) Cancer Epidemiol Biomarkers Prev. 2019 Oct;28(10):1642-1651.
Gleason Probability Maps: A Radiomics Tool for Mapping Prostate Cancer Likelihood in MRI Space.

(McGarry SD, Bukowy JD, Iczkowski KA, Unteriner JG, Duvnjak P, Lowman AK, Jacobsohn K, Hohenwalter M, Griffin MO, Barrington AW, Foss HE, Keuter T, Hurrell SL, See WA, Nevalainen MT, Banerjee A, LaViolette PS.) Tomography. 2019 03;5(1):127-134.
Targeting the STAT5 pathway in Ph+ acute lymphoblastic leukemia.

(Minieri V, De Dominici M, Nevalainen MT, Calabretta B.) Oncotarget. 2018 Dec 04;9(95):36726-36727.
Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia.

(Minieri V, De Dominici M, Porazzi P, Mariani SA, Spinelli O, Rambaldi A, Peterson LF, Porcu P, Nevalainen MT, Calabretta B.) Cancer Res. 2018 10 15;78(20):5793-5807.
Radio-pathomic Maps of Epithelium and Lumen Density Predict the Location of High-Grade Prostate Cancer.

(McGarry SD, Hurrell SL, Iczkowski KA, Hall W, Kaczmarowski AL, Banerjee A, Keuter T, Jacobsohn K, Bukowy JD, Nevalainen MT, Hohenwalter MD, See WA, LaViolette PS.) Int J Radiat Oncol Biol Phys. 2018 08 01;101(5):1179-1187.
STAT5A/B Blockade Sensitizes Prostate Cancer to Radiation through Inhibition of RAD51 and DNA Repair.

(Maranto C, Udhane V, Hoang DT, Gu L, Alexeev V, Malas K, Cardenas K, Brody JR, Rodeck U, Bergom C, Iczkowski KA, Jacobsohn K, See W, Schmitt SM, Nevalainen MT.) Clin Cancer Res. 2018 04 15;24(8):1917-1931.
Optimized -value selection for the discrimination of prostate cancer grades, including the cribriform pattern, using diffusion weighted imaging.

(Hurrell SL, McGarry SD, Kaczmarowski A, Iczkowski KA, Jacobsohn K, Hohenwalter MD, Hall WA, See WA, Banerjee A, Charles DK, Nevalainen MT, Mackinnon AC, LaViolette PS.) J Med Imaging (Bellingham). 2018 01;5(1):011004.
Erratum: ETS Related Gene mediated Androgen Receptor Aggregation and Endoplasmic Reticulum Stress in Prostate Cancer Development.

(Sreenath TL, Macalindong SS, Mikhalkevich N, Sharad S, Mohamed A, Young D, Borbiev T, Xavier C, Gupta R, Jamal M, Babcock K, Tan SH, Nevalainen MT, Dobi A, Petrovics G, Sesterhenn IA, Rosner IL, Bieberich CJ, Nelson P, Vasioukhin V, Srivastava S.) Sci Rep. 2017 09 06;7(1):10693.
ETS Related Gene mediated Androgen Receptor Aggregation and Endoplasmic Reticulum Stress in Prostate Cancer Development.

(Sreenath TL, Macalindong SS, Mikhalkevich N, Sharad S, Mohamed A, Young D, Borbiev T, Xavier C, Gupta R, Jamal M, Babcock K, Tan SH, Nevalainen MT, Dobi A, Petrovics G, Sesterhenn IA, Rosner IL, Bieberich CJ, Nelson P, Vasioukhin V, Srivastava S.) Sci Rep. 2017 04 24;7(1):1109.
Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.

(Hoang DT, Iczkowski KA, Kilari D, See W, Nevalainen MT.) Oncotarget. 2017 Jan 10;8(2):3724-3745.
miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1.

(Wang Y, Lieberman R, Pan J, Zhang Q, Du M, Zhang P, Nevalainen M, Kohli M, Shenoy NK, Meng H, You M, Wang L.) Mol Cancer. 2016 11 10;15(1):70.
Jak2/Stat5a/b pathway in prostate cancer

(Nevalainen M, Gupta S.) Cancer Therapeutic Targets. 1 January 2017;2-2:745-752.

Marja T. Nevalainen, MD, PhD